Eloxx Pharmaceuticals, Inc. (ELOX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Eloxx Pharmaceuticals reported revenue of $0. Net income was -$6.0M, or -$0.49 per diluted share. Operating activities generated -$6.3M of cash. At fiscal year end, Eloxx Pharmaceuticals held $5.3M in total assets against $17.2M in total liabilities, including $4.8M of cash and equivalents.
Open the full interactive Eloxx Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Eloxx Pharmaceuticals Key Stats
| Share Price | $12.70 |
|---|---|
| Market Cap | $86.2M |
| 52-Week Range | $10.95 – $20.98 |
| Shares Outstanding | 6.8 million (basic, 2026 Q2) |
Eloxx Pharmaceuticals Income Statement
| FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$47.6M | -$50.6M | -$33.5M | -$66.0M | -$34.4M | -$6.4M |
| Pre-Tax Income | -$47.1M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$6.0M |
| Income Tax | $122,000 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$47.2M | -$50.9M | -$34.6M | -$66.7M | -$36.1M | -$6.0M |
| Diluted EPS | -$1.45 | -$1.34 | -$0.86 | -$0.95 | -$16.65 | -$0.49 |
Eloxx Pharmaceuticals Quarterly Results
| 2023 Q2 | 2023 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.3M | -$3.6M | -$3.8M | -$4.5M |
| Diluted EPS | -$1.96 | -$1.31 | -$0.08 | -$0.66 |
Eloxx Pharmaceuticals Balance Sheet
| FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $48.6M | $22.5M | $24.7M | $42.3M | $19.2M | $4.8M |
| Current Assets | $50.3M | $57.7M | $25.9M | $43.5M | $20.1M | $5.3M |
| Total Assets | $50.7M | $58.9M | $26.5M | $45.1M | $21.1M | $5.3M |
| Current Liabilities | $7.8M | $11.8M | $9.8M | $10.0M | $23.1M | $17.2M |
| Total Long-Term Debt | — | $14.8M | $11.6M | $12.0M | $12.5M | $2.0M |
| Total Liabilities | $7.8M | $22.7M | $16.2M | $22.8M | $31.8M | $17.2M |
| Shareholders' Equity | $42.9M | $36.2M | $10.2M | $22.4M | -$10.7M | -$11.9M |
Eloxx Pharmaceuticals Cash Flow Statement
| FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$31.4M | -$39.4M | -$28.2M | -$35.0M | -$31.8M | -$6.3M |
| Cash From Investing | -$317,000 | -$33.5M | $33.8M | $2.1M | -$66,000 | $1,000 |
| Cash From Financing | $56.2M | $46.8M | -$3.4M | $50.8M | $8.8M | $11.0M |
| Free Cash Flow | -$31.6M | -$39.4M | -$28.2M | -$35.1M | -$31.9M | — |
| Dividends Paid | $0 | $0 | — | — | — | — |
Figures from Eloxx Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Eloxx Pharmaceuticals financials page for every line item.
Eloxx Pharmaceuticals Company Profile
| Ticker | ELOX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Arlington, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001035354 |
Frequently Asked Questions
What was Eloxx Pharmaceuticals' revenue in fiscal 2025?
Eloxx Pharmaceuticals (ELOX) reported revenue of $0 for fiscal 2025.
What is Eloxx Pharmaceuticals' annual revenue history?
Eloxx Pharmaceuticals' annual revenue by fiscal year: 2018: $0; 2019: $0; 2020: $0; 2021: $0; 2022: $0; 2025: $0.
What was Eloxx Pharmaceuticals' net income in fiscal 2025?
Eloxx Pharmaceuticals reported net income of -$6.0M for fiscal 2025.
What was Eloxx Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Eloxx Pharmaceuticals' diluted EPS was -$0.49 for fiscal 2025 (adjusted for any later stock splits).
What was Eloxx Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Eloxx Pharmaceuticals reported revenue of $0.
How much debt does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals reported $2.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Eloxx Pharmaceuticals are outstanding?
Eloxx Pharmaceuticals reported a weighted average of 6.8 million basic shares outstanding in 2026 Q2.
What is Eloxx Pharmaceuticals' market cap?
Based on its latest closing price, Eloxx Pharmaceuticals (ELOX) has a market capitalization of about $86.2M.
When does Eloxx Pharmaceuticals' fiscal year end?
Eloxx Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Eloxx Pharmaceuticals headquartered?
Eloxx Pharmaceuticals lists its business address in Arlington, Massachusetts in its SEC filings.
Eloxx Pharmaceuticals Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →